| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1948 |
| Trial ID | NCT03628612 |
| Disease | Acute Lymphoblastic Leukemia | Diffuse Large B-Cell Lymphoma | Multiple Myeloma | T-Cell Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AUTO-LT1 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified |
| Year | 2018 |
| Country | United Kingdom |
| Company sponsor | Autolus Limited |
| Other ID(s) | AUTO-LT1 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||